search
Back to results

Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes (Insight Kids)

Primary Purpose

Diabetes Mellitus Type 1

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Accu-Chek Insight Pump System
Sponsored by
Hoffmann-La Roche
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Diabetes Mellitus Type 1

Eligibility Criteria

2 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Children and adolescents at least 24 months of age, and not more than 17 years of age at screening
  • Diagnosed with type 1 diabetes
  • Diagnosis of type 1 diabetes established > 6 months before study start if >5 years of age
  • Indication for insulin pump therapy according to local guidelines
  • Subject's most recent HbA1c is equal or above 7.0% (53.0 mmol/mol) - measured at last assessment before screening within the past 2 months prior to the Baseline Visit into the study
  • Willingness to use automated bolus advice obtained from the Accu-Chek Insight diabetes therapy system during the study
  • Willingness and ability to participate and comply with study procedures

Exclusion Criteria:

  • Disease or condition that in the opinion of the investigator is likely to affect compliance or the ability to complete the study
  • Not willing or able to start insulin pump therapy
  • Not willing to self-measure blood glucose at least four times daily
  • Significantly impaired awareness of hypoglycemia
  • More than one hospitalization for severe hypoglycemia during the last 12 months
  • History of recurrent ketoacidosis during intensive insulin therapy
  • Known strong plaster incompatibility and/or allergy
  • Unstable chronic disease other than diabetes (e.g. impaired hepatic function, impaired renal function, impaired cardiac function, uncontrolled vascular complications) and any other condition interfering with the study procedures, as per Investigator´s discretion.
  • If on antihypertensive, thyroid, anti-depressant or lipid-lowering medication, lack of stability on the medication for the past 2 months prior to the Baseline Visit in the study
  • Chronic use of steroids in adrenal suppressive doses, other immuno-modulatory medication or chemotherapy
  • Prescription medications other than insulin interfering with diabetes management
  • Acute illness or abnormality (e.g. impaired vision, impaired motor function, acute pain) at the time of screening interfering with study procedures, affecting compliance, or the ability to complete the study as per Investigator´s discretion
  • Either pregnant or breastfeeding
  • Drug dependency
  • Dependency on sponsor or Investigator (e.g. co-worker or family member)

Sites / Locations

  • Medical University Graz
  • Universitatsklinik fur PadiatrieI, Padiatrische Diabetologie und Endokrinologie
  • Medical University of Vienna-Dept of Pediatrics
  • Kinderkrankenhaus auf der Bult
  • Gemeinschaftspraxis für Kinder- und Jugendmedizin
  • Practice for Pediatric and Adolescent Diabetology
  • Universitatsklinikum Tubingen
  • Birmingham Children's Hospital Foundation Trust
  • St. James's University Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Continuous Subcutaneous Insulin Infusion (CSII)

Arm Description

Continuous Subcutaneous Insulin Infusion (CSII) in Children and Adolescents 2-17 Years of Age

Outcomes

Primary Outcome Measures

Percentage of Children and Adolescents of Ages 2 to 17 Years Reaching an HbA1c target of <7.5%
This HbA1c target of <7.5% proportion is statistically tested against a proportion of 25%, composed of the anticipated population proportion of 15% of children and adolescents using multiple daily insulin injections plus a safety margin of 10%.

Secondary Outcome Measures

Score on Insulin Pump Questionnaire
Score on Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Score on Pediatric Quality of Life Inventory (PedsQL)
Change from Baseline in HbA1c
Change from Baseline in Blood Glucose
Number of Subjects, Who Report a Diabetes-Related Adverse Event (i.e., Symptomatic Hypoglycemia, Severe Hypoglycemia, Diabetic Ketoacidosis)

Full Information

First Posted
March 26, 2015
Last Updated
November 23, 2017
Sponsor
Hoffmann-La Roche
Collaborators
Roche Diabetes Care GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT02403375
Brief Title
Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes
Acronym
Insight Kids
Official Title
Insight Kids Study: Reaching HbA1c Targets in Children and Adolescents With Type 1 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
May 17, 2015 (Actual)
Primary Completion Date
October 26, 2017 (Actual)
Study Completion Date
October 26, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche
Collaborators
Roche Diabetes Care GmbH

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This study is to compare metabolic control, treatment satisfaction, and quality of life during continuous subcutaneous insulin infusion (CSII ) therapy with a new insulin pump system with multiple daily injections (MDI) therapy. Furthermore, this study will add clinical data originating from clinical investigation in a special population, i.e. children and adolescents of ages 2 - 17 years , to the existing clinical data of the ACCU-CHEK Insight insulin pump.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus Type 1

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
43 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Continuous Subcutaneous Insulin Infusion (CSII)
Arm Type
Experimental
Arm Description
Continuous Subcutaneous Insulin Infusion (CSII) in Children and Adolescents 2-17 Years of Age
Intervention Type
Device
Intervention Name(s)
Accu-Chek Insight Pump System
Intervention Description
Continuous subcutaneous insulin infusion pump
Primary Outcome Measure Information:
Title
Percentage of Children and Adolescents of Ages 2 to 17 Years Reaching an HbA1c target of <7.5%
Description
This HbA1c target of <7.5% proportion is statistically tested against a proportion of 25%, composed of the anticipated population proportion of 15% of children and adolescents using multiple daily insulin injections plus a safety margin of 10%.
Time Frame
26 weeks
Secondary Outcome Measure Information:
Title
Score on Insulin Pump Questionnaire
Time Frame
26 weeks
Title
Score on Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Time Frame
26 weeks
Title
Score on Pediatric Quality of Life Inventory (PedsQL)
Time Frame
26 weeks
Title
Change from Baseline in HbA1c
Time Frame
26 weeks
Title
Change from Baseline in Blood Glucose
Time Frame
26 weeks
Title
Number of Subjects, Who Report a Diabetes-Related Adverse Event (i.e., Symptomatic Hypoglycemia, Severe Hypoglycemia, Diabetic Ketoacidosis)
Time Frame
26 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children and adolescents at least 24 months of age, and not more than 17 years of age at screening Diagnosed with type 1 diabetes Diagnosis of type 1 diabetes established > 6 months before study start if >5 years of age Indication for insulin pump therapy according to local guidelines Subject's most recent HbA1c is equal or above 7.0% (53.0 mmol/mol) - measured at last assessment before screening within the past 2 months prior to the Baseline Visit into the study Willingness to use automated bolus advice obtained from the Accu-Chek Insight diabetes therapy system during the study Willingness and ability to participate and comply with study procedures Exclusion Criteria: Disease or condition that in the opinion of the investigator is likely to affect compliance or the ability to complete the study Not willing or able to start insulin pump therapy Not willing to self-measure blood glucose at least four times daily Significantly impaired awareness of hypoglycemia More than one hospitalization for severe hypoglycemia during the last 12 months History of recurrent ketoacidosis during intensive insulin therapy Known strong plaster incompatibility and/or allergy Unstable chronic disease other than diabetes (e.g. impaired hepatic function, impaired renal function, impaired cardiac function, uncontrolled vascular complications) and any other condition interfering with the study procedures, as per Investigator´s discretion. If on antihypertensive, thyroid, anti-depressant or lipid-lowering medication, lack of stability on the medication for the past 2 months prior to the Baseline Visit in the study Chronic use of steroids in adrenal suppressive doses, other immuno-modulatory medication or chemotherapy Prescription medications other than insulin interfering with diabetes management Acute illness or abnormality (e.g. impaired vision, impaired motor function, acute pain) at the time of screening interfering with study procedures, affecting compliance, or the ability to complete the study as per Investigator´s discretion Either pregnant or breastfeeding Drug dependency Dependency on sponsor or Investigator (e.g. co-worker or family member)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cosima Rieger, Dr.
Organizational Affiliation
Roche Diabetes Care GmbH
Official's Role
Study Director
Facility Information:
Facility Name
Medical University Graz
City
Graz
ZIP/Postal Code
8036
Country
Austria
Facility Name
Universitatsklinik fur PadiatrieI, Padiatrische Diabetologie und Endokrinologie
City
Innsbruck
ZIP/Postal Code
6020
Country
Austria
Facility Name
Medical University of Vienna-Dept of Pediatrics
City
Vienna
ZIP/Postal Code
1090
Country
Austria
Facility Name
Kinderkrankenhaus auf der Bult
City
Hannover
ZIP/Postal Code
30173
Country
Germany
Facility Name
Gemeinschaftspraxis für Kinder- und Jugendmedizin
City
Herford
ZIP/Postal Code
32051
Country
Germany
Facility Name
Practice for Pediatric and Adolescent Diabetology
City
Munster
ZIP/Postal Code
48155
Country
Germany
Facility Name
Universitatsklinikum Tubingen
City
Tubingen
ZIP/Postal Code
72076
Country
Germany
Facility Name
Birmingham Children's Hospital Foundation Trust
City
Birmingham
ZIP/Postal Code
B46NH
Country
United Kingdom
Facility Name
St. James's University Hospital
City
Leeds
ZIP/Postal Code
LS97TF
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes

We'll reach out to this number within 24 hrs